10-12 October, 2017
Frankfurt, Germany

Pre Conference Workshop A
Tuesday 10th October, 2017

10.00 - 13.00
Effectively Build Entry Strategies into the European NASH Market

With a continually growing patient population and no approved treatments, NASH presents a huge unmet clinical need. Drug developers are racing to bring an effective therapeutic to market as
quickly as possible. However, developing a robust market entry strategy for Europe is not without its challenges. Join your peers and industry leading experts at this workshop to learn how to navigate the European drug development landscape.

Attend this expert led workshop to:

  • Gain a comprehensive understanding of the drivers of NASH disease and challenges ahead in bringing a drug to market in the European landscape.
  • Quantify the enormity of the clinical and economic burdens of NAFLD/NASH, which will likely increase as the incidence of NAFLD continues to rise.
  • Predict what the next 12 months hold for NASH drug development in Europe.

Workshop Leader: George O’Rourke, Managing Director, GO Biotech Consulting

Pre Conference Workshop B
Tuesday 10th October, 2017

14.00 - 17.00
Improving Understanding of Molecular Mechanisms that are Driving NASH & Robustly Testing Your Hypothesis Preclinically

The molecular mechanisms triggering NASH in the liver are unknown. Currently, there is a lack of industry consensus on the mechanisms driving NASH disease and therefore which are the most appropriate to target therapeutically.

Furthermore, replicating human NASH disease in vivo is one of the most challenging aspects of preclinical drug development. Currently there are a plethora of animal models available, however, no mice model completely fulfils the clinical features observed in humans.

This workshop will review the latest advances in understanding the molecular mechanisms driving NASH disease. We will review commonly used animal models of NAFLD/NASH referring to their advantages and disadvantages. You will leave this workshop with a comprehensive understanding of potential mechanisms driving NASH and which mouse models are most appropriate for your NASH candidate.

Join this workshop to:

  • Discuss the mechanisms by which inflammation is triggered.
  • Objectively review the plethora of animal models available for NASH and highlight their advantages and disadvantages.
  • Learn how to comprehensively test your NASH drugs mode of action in the most appropriate models for that drug.

Workshop Leader: Ronit Shiri-Sverdlov, Professor, Hepatic Inflammation and Metabolic Health, Maastricht University